Piramal Pharma Acquires Yapan Bio
Piramal Pharma strengthens its biologics CDMO business, converting Yapan Bio from associate company to subsidiary and expanding vaccine and biologics manufacturing capabilities.
Piramal Pharma completed the acquisition of an incremental 40.67% stake in Yapan Bio, a Hyderabad-based CDMO specializing in vaccines and biologics, for an aggregate cash consideration of ₹76 crore INR, or $7.95 million. As a result of this transaction, Piramal Pharma now owns 74% of Yapan Bio's equity, making Yapan Bio a subsidiary of PPL.
Finalized on August 18, 2026, the acquisition marks a major step forward in Piramal's long-range plan to expand its presence in the biologics sector. With the finalization of this deal, Piramal will fully embed the subsidiary's advanced large molecule capabilities into its integrated service offering, enabling the Company to offer customers broader services in the space and expanding its ability to develop and scale complex biologic therapies with greater efficiency. The subsidiary will continue to operate within the structure of Piramal Pharma Solutions, the CDMO arm of Piramal Pharma.
Yapan Bio also directly supports ADCelerate, Piramal Pharma Solutions' fixed-price, integrated platform that streamlines Phase I ADC development from R&D to GMP in as little as 12 months. This acquisition further enhances ADCelerate and reinforces Piramal's ability to deliver life-saving ADCs to market with speed and consistency.
"This strategic investment doesn't just fuel our long-term growth; it also puts Patient Centricity into action," said Peter DeYoung, CEO, Piramal Global Pharma. "By integrating Yapan Bio's specialized expertise into our global network, we're empowering our partners to meet a rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need."
